INTRODUCTION: Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma. However, Immune checkpoint inhibitors often induce various immune-related adverse events. CASE PRESENTATION: The patient was a 78-year-old woman with lung adenocarcinoma who had a partial response to pembrolizumab. During treatment, she complained of pollakiuria and nocturia with painful micturition. Histological analysis revealed…
IJU Case Reports Template
Write in a clean editor, then format for IJU Case Reports in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the IJU Case Reports format
IJU Case Reports is a peer-reviewed journal published by Wiley, covering Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment, Urinary and Genital Oncology Studies.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." IJU Case Reports 12 (3): 45–58.
Formats any DOI in IJU Case Reports style. No sign-up. |
| Publishes research in | Bladder and Urothelial Cancer Treatments Renal cell carcinoma treatment Urinary and Genital Oncology Studies Ureteral procedures and complications Urological Disorders and Treatments |
| ISSN | 2577-171X |
| Citation impact (2-yr) | 0.4 |
| h-index | 12 |
| i10-index | 28 |
| Total citations | 1,998 |
| Article processing charge | $2,530 |
| Open access | Yes |
| Top institutions publishing here | Nagoya City University |
| Journal website | onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in IJU Case Reports per year
Citation impact of IJU Case Reports by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in IJU Case Reports
INTRODUCTION: Pembrolizumab cause immune-related adverse events. We herein report a case of advanced bladder cancer, who treated with pembrolizumab and exhibited intriguing clinical course. CASE PRESENTATION: A 63-year-old man with bladder carcinoma was treated by radical cystectomy, however, the bladder carcinoma recurred and invaded to the rectum. He was treated by combination therapy using gemcitabine…
INTRODUCTION: Apalutamide-associated skin rash is a more common adverse event in the Japanese population than in the global population. However, its mechanism remains elusive, and limited histopathological information hampers further understanding. CASE PRESENTATION: Case 1: a 71-year-old man with metastatic castration-sensitive prostate cancer developed a skin rash after 70 days of apalutamide treatment. Case 2:…
Introduction Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. Case presentation We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of…
INTRODUCTION: Paraganglioma of the urinary bladder is a very rare disease accounting for 0.06% of all bladder tumors. Owing to their rarity and symptomatic variability, preoperative diagnosis is often difficult. CASE PRESENTATION: A 70-year-old male was referred to our department for hematuria. Cystoscopy showed a non-papillary broad-based tumor. Computed tomography and magnetic resonance imaging revealed…